Interventions to optimise prescribing for older people in care homes (Review)

Alldred DP, Raynor DK, Hughes C, Barber N, Chen TF, Spoor P

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2013, Issue 2

http://www.thecochranelibrary.com

WILEY
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Header</td>
<td>1</td>
</tr>
<tr>
<td>Abstract</td>
<td>1</td>
</tr>
<tr>
<td>Plain Language Summary</td>
<td>2</td>
</tr>
<tr>
<td>Summary of Findings for the Main Comparison</td>
<td>3</td>
</tr>
<tr>
<td>Background</td>
<td>3</td>
</tr>
<tr>
<td>Objectives</td>
<td>5</td>
</tr>
<tr>
<td>Methods</td>
<td>5</td>
</tr>
<tr>
<td>Results</td>
<td>7</td>
</tr>
<tr>
<td>Figure 1</td>
<td>9</td>
</tr>
<tr>
<td>Figure 2</td>
<td>12</td>
</tr>
<tr>
<td>Figure 3</td>
<td>13</td>
</tr>
<tr>
<td>Discussion</td>
<td>16</td>
</tr>
<tr>
<td>Authors’ Conclusions</td>
<td>17</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>17</td>
</tr>
<tr>
<td>References</td>
<td>18</td>
</tr>
<tr>
<td>Characteristics of Studies</td>
<td>20</td>
</tr>
<tr>
<td>Data and Analyses</td>
<td>38</td>
</tr>
<tr>
<td>Additional Tables</td>
<td>38</td>
</tr>
<tr>
<td>Appendices</td>
<td>39</td>
</tr>
<tr>
<td>Contributions of Authors</td>
<td>51</td>
</tr>
<tr>
<td>Declarations of Interest</td>
<td>52</td>
</tr>
<tr>
<td>Sources of Support</td>
<td>52</td>
</tr>
<tr>
<td>Differences Between Protocol and Review</td>
<td>52</td>
</tr>
<tr>
<td>Index Terms</td>
<td>52</td>
</tr>
</tbody>
</table>
ABSTRACT

Background

There is a substantial body of evidence that prescribing for care home residents is suboptimal and requires improvement. Consequently, there is a need to identify effective interventions to optimise prescribing and resident outcomes in this context.

Objectives

The objective of the review was to determine the effect of interventions to optimise prescribing for older people living in care homes.

Search methods

We searched the Cochrane Effective Practice and Organisation of Care (EPOC) Group Specialised Register; Cochrane Central Register of Controlled Trials (CENTRAL), The Cochrane Library (Issue 11, 2012); Cochrane Database of Systematic Reviews, The Cochrane Library (Issue 11, 2012); MEDLINE OvidSP (1980 on); EMBASE, Ovidsp (1980 on); Ageline, EBSCO (1966 on); CINAHL, EBSCO (1980 on); International Pharmaceutical Abstracts, OvidSP (1980 on); PsycINFO, OvidSP (1980 on); conference proceedings in Web of Science, Conference Proceedings Citation Index - SSH & Science, ISI Web of Knowledge (1990 on); grey literature sources and trial registries; and contacted authors of relevant studies. We also reviewed the references lists of included studies and related reviews (search period November 2012).

Selection criteria

We included randomised controlled trials evaluating interventions aimed at optimising prescribing for older people (aged 65 years or older) living in institutionalised care facilities. Studies were included if they measured one or more of the following primary outcomes, adverse drug events; hospital admissions; mortality; or secondary outcomes, quality of life (using validated instrument); medication-related problems; medication appropriateness (using validated instrument); medicine costs.

Data collection and analysis

Two authors independently screened titles and abstracts, assessed studies for eligibility, assessed risk of bias and extracted data. A narrative summary of results was presented.
Main results

The eight included studies involved 7653 residents in 262 (range 1 to 85) care homes in six countries. Six studies were cluster-randomised controlled trials and two studies were patient-randomised controlled trials. The interventions evaluated were diverse and often multifaceted. Medication review was a component of seven studies, three studies involved multidisciplinary case-conferencing, two studies involved an educational element for care home staff and one study evaluated the use of clinical decision support technology. Due to heterogeneity, results were not combined in a meta-analysis. There was no evidence of an effect of the interventions on any of the primary outcomes of the review (adverse drug events, hospital admissions and mortality). No studies measured quality of life. There was evidence that the interventions led to the identification and resolution of medication-related problems. There was evidence from two studies that medication appropriateness was improved. The evidence for an effect on medicine costs was equivocal.

Authors’ conclusions

Robust conclusions could not be drawn from the evidence due to variability in design, interventions, outcomes and results. The interventions implemented in the studies in this review led to the identification and resolution of medication-related problems, however evidence of an effect on resident-related outcomes was not found. There is a need for high-quality cluster-randomised controlled trials testing clinical decision support systems and multidisciplinary interventions that measure well-defined, important resident-related outcomes.

PLAIN LANGUAGE SUMMARY

Interventions to optimise prescribing for older people in care homes

Older people living in care homes (also called nursing homes, residential homes, skilled-nursing facilities, assisted-living facilities or aged-care facilities) have many complex physical and mental health problems. Care home residents are prescribed many medicines compared to people who live in their own homes, with an average of eight medicines being common. International research has shown that these medicines are often not well managed, with some residents prescribed medicines inappropriately. This has the potential to lead to harmful side effects and a loss of benefit. For these reasons, it is important to make sure that care home residents are prescribed the right medicines at the right doses.

This review found eight studies involving 7653 residents in 262 care homes in six countries that evaluated interventions to optimise prescribing for care home residents. Most of the interventions had several components, often involving a review of medicines with a pharmacist and doctor. Some interventions included a teaching component and one study used Information Technology.

There was no evidence of benefit of the interventions with respect to reducing adverse drug events (harmful effects caused by medicines), hospital admissions or death. None of the studies looked at quality of life. Problems relating to medicines were found and addressed through the interventions used in the studies. Prescribing was improved based on criteria used to assess the appropriateness of prescribing in two studies.

More high-quality studies need to be done to gather more evidence for these and other types of interventions. Further studies are needed to evaluate new technologies, including computer systems that support prescribing decisions. More work needs to be done to make sure that researchers are consistently measuring outcomes that are important to care home residents.
### SUMMARY OF FINDINGS FOR THE MAIN COMPARISON

**Medication review compared with usual GP care for optimising prescribing for care home residents**

**Patient or population:** older people (aged 65 years or older) living in care homes  
**Settings:** Institutionalised care facilities in Australia, Netherlands, Sweden, United Kingdom and USA and Canada  
**Intervention:** Medication review as a single intervention or a component of a multi-faceted intervention  
**Comparison:** Usual care by general practitioner

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Impact</th>
<th>No of Participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse drug events</td>
<td>There was no evidence of an effect on adverse drug events</td>
<td>110 in 85 care homes (1 study)</td>
<td>⊕⊕⊕⊕ low</td>
</tr>
<tr>
<td>Hospital admissions</td>
<td>There was no evidence of an effect on hospital admissions</td>
<td>4306 in 216 care homes (4 studies)</td>
<td>⊕⊕⊕⊕ low</td>
</tr>
<tr>
<td>Mortality</td>
<td>There was no evidence of an effect on mortality</td>
<td>4221 in 131 care homes (3 studies)</td>
<td>⊕⊕⊕⊕ low</td>
</tr>
<tr>
<td>Quality of life</td>
<td>No studies reported quality of life</td>
<td>0 (no studies)</td>
<td>-</td>
</tr>
<tr>
<td>Medication-related problems</td>
<td>Medication review may lead to the identification and resolution of medication-related problems</td>
<td>6281 in 250 care homes (6 studies)</td>
<td>⊕⊕⊕⊕ low</td>
</tr>
<tr>
<td>Medication appropriateness</td>
<td>Medication review may lead to an improvement in medication appropriateness</td>
<td>264 in 95 care homes (2 studies)</td>
<td>⊕⊕⊕⊕ low</td>
</tr>
<tr>
<td>Medicine costs</td>
<td>It is uncertain whether medication review decreases medication costs</td>
<td>4375 in 141 care homes (4 studies)</td>
<td>⊕⊕⊕⊕ very low</td>
</tr>
</tbody>
</table>

**GRADE Working Group grades of evidence**  
**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.  
**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  
**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  
**Very low quality:** We are very uncertain about the estimate.

The *Gurwitz 2008* study is not included in the ‘Summary of findings’ table as medication review was not a component of the intervention.

### BACKGROUND

Globally, the proportion of older people in the population is increasing. The proportion of people aged 60 years and over was 11% in 2009 and this is projected to double by the middle of this
century (United Nations 2009), with developed countries experiencing the fastest rise in number of older people. In the United Kingdom (UK), it is estimated that by 2034 nearly a quarter of the population will be aged 65 years and over. The most rapid rise has been in the ‘oldest old’ that is those aged 85 years and over; it is projected that by 2034 there will be a 2.5 fold increase in the number of the oldest old, representing 5% of the population (Office for National Statistics 2010). As a consequence, there will continue to be an increasing demand for long-term care across the world.

Long-term care may be provided in people’s homes or in institutional facilities such as nursing homes or hospitals. The terminology used to describe homes that provide care for older people (defined as 65 years or older (Department of Health 2001)) differs across the world. In the UK the homes are known as ‘care homes’, in the United States (US) ‘long-term care facilities’ and in Australia ‘aged-care facilities’. Care homes are usually classified into two main categories, those that provide 24 hour nursing care (nursing homes in the UK, skilled-nursing facilities in the US and aged-care facilities providing high-level care in Australia); and those that provide personal care (residential homes in the UK, assisted-living in the US and aged-care facilities providing low-level care in Australia). Some care homes provide both types of care.

Older people living in care homes are often frail, and they are one of the most vulnerable groups in society. They have complex health needs due to multiple co-morbidities and age-related changes in pharmacokinetics and pharmacodynamics (Armour 2002). Polypharmacy, usually defined as greater than four or more medicines (Department of Health 2001; Rollason 2003; Patterson 2012), is common in this setting across the world with residents prescribed an increasing number of medicines over the last decade or so. In the UK, the mean number of medicines prescribed per resident was 4.9 in 1998 (Furniss 2000), 6.9 in 2003 (Zermansky 2006), and by 2007 this had risen to 8.0 (Barber 2009). Many care home residents also have cognitive impairment and this can impede their ability to communicate medicine-related problems (Matthews 2002; Alldred 2007a).

The complexity of prescribing for this population is compounded by multiple clinicians prescribing. This may involve family physicians and community-based consultants (for example old age psychiatrists and geriatricians) in primary care; and secondary care doctors from multiple specialties. In addition, the lack of representation of older people in clinical trials limits the evidence base and further increases the complexity (Beglinger 2008). It is, therefore, perhaps unsurprising that there is extensive evidence that prescribing is suboptimal for care home residents. Inappropriate prescribing, measured using validated, explicit and implicit definitions, has been found to be common in nursing and residential homes in several countries including the US (Beers 1992; Hanlon 1996; Sloane 2002; Gray 2003; Lau 2005; Perri 2005), Canada (Brymer 2003), the UK (Oborne 2003) and Australia (Crotty 2004).

Perri 2005 found that over a one month duration, 47% of 1117 residents of 15 US nursing homes received at least one inappropriate medicine, with 13% of residents having at least one adverse health outcome. Inappropriate prescribing more than doubled the risk of a resident experiencing at least one adverse health outcome (odds ratio (OR) 2.34, 95% confidence interval (CI) 1.61-3.40). Lau 2005 reported that 50% of 3372 US nursing home residents were prescribed at least one inappropriate medicine over one year. The risks of hospitalisation and death were greater in those residents exposed to an inappropriate medicine (OR 1.27, 95% CI 1.09-1.47; OR 1.28, 95% CI 1.05-1.55, respectively). Gray 2003 found that 22% of 282 US residents of residential care facilities were prescribed at least one inappropriate medicine. There is also evidence that care home residents are under-prescribed beneficial drugs and are poorly monitored with respect to their long-term conditions and their medicines (Fahey 2003; Alldred 2007b; Barber 2009).

For the reasons discussed above, care home residents are particularly susceptible to adverse drug events. In two US long-term care facilities, Gurwitz 2005 found 9.8 adverse drug events per 100 resident-months, with 42% being judged as preventable. Drug-related problems have been found to be responsible for 3% to 31% of hospital admissions of older people, and up to half of these are potentially avoidable (Howard 2007).

Description of the condition

As described above, suboptimal prescribing for older people living in care homes is common and may occur due to the prescribing of inappropriate medicines, the omission of beneficial medicines or the failure to appropriately monitor residents and the effects of their medicines. There are a variety of instruments that can be employed to measure the appropriateness of prescribing in older people (Spinewine 2007). However, the predictive validity of these instruments on health outcomes such as adverse drug events and hospital admissions has not been unequivocally established (Spinewine 2007).

Description of the intervention

For this review, we were interested in interventions concerned with optimising the whole medication regime for care home residents, not those concentrating solely on isolated drugs or classes such as benzodiazepines or antipsychotics nor those concentrating on one disease state. Financial and regulatory interventions tend to fall into this latter category. There are several types of interventions that can potentially optimise prescribing in this setting, including:

- professional interventions, for example educational programmes aimed at prescribers;
• organisational interventions, for example medication review services or specialist clinics, case conferencing, information and communication technology (ICT) interventions such as clinical decision support systems.

Medication review interventions may be aimed at specific drugs or the whole regime and can be uni- or multiprofessional, involving physicians, nurses and pharmacists.

How the intervention might work
Interventions designed to improve prescribing for care home residents may have an impact by discontinuing inappropriate medication; commencing beneficial medicines; and ensuring appropriate monitoring of long-term conditions and medicines. Consequently, this may lead to a reduction in adverse drug events, improved quality of life and a reduction in medicine costs.

Why it is important to do this review
There is a substantial body of evidence that prescribing for care home residents is suboptimal and requires improvement. As well, there are other Cochrane reviews being undertaken which address similar issues in different populations (Soe 2009; Christensen 2011). We evaluated the evidence for interventions to address suboptimal prescribing in this setting to identify how care can be improved for this frail and vulnerable population. We intended to achieve this by determining which interventions were effective and by identifying gaps in the evidence to inform future research.

OBJECTIVES
The objective of the review was to determine the effect of interventions to optimise overall prescribing for older people living in care homes.

METHODS

Criteria for considering studies for this review

Types of studies
We included patient-randomised controlled trials (P-RCT) and cluster-randomised controlled trials (C-RCT).

Types of participants
We included studies of older people (aged 65 years or older) living in institutionalised care facilities. Institutionalised care facilities include: nursing homes and residential homes (UK); skilled-nursing facilities and assisted-living facilities (US); and aged-care facilities providing low-level and high-level care (Australia). If there was any ambiguity in the description of the institution, we clarified this with the authors of relevant papers. We considered trials for inclusion if they had a majority (80% or more) of participants aged 65 years or more, or if the mean age was greater than 65 years. We excluded studies where the intervention focused on a single medical condition or a specific drug or class of drugs. We also excluded studies where the main focus was to reduce medication errors because such studies have a narrow focus and do not consider the whole medication regime. In addition, they do not seek to optimise prescribing, for example by adhering to evidence-based guidelines or by reducing inappropriate prescribing, but are designed to solely reduce errors.

Types of interventions
We assessed interventions aimed at optimising prescribing for care home residents compared with usual care as defined by the study. These interventions potentially included: educational interventions aimed at prescribers; medication review services (uni or multiprofessional, conducted by nurses, pharmacists or physicians); case conferencing; and ICT interventions such as clinical decision support systems. We excluded financial and regulatory interventions.

Types of outcome measures
We included a range of outcome measures including patient-related outcomes, health service utilisation, and economic outcomes. Studies were included if they reported at least one primary outcome measure or at least one secondary outcome measure.

Primary outcomes
The primary outcome measures for the review were:
1. adverse drug events;
2. hospital admissions;
3. mortality.

Secondary outcomes
Secondary outcome measures were:
1. quality of life (using validated instrument);
2. medication-related problems;
3. medication appropriateness (using validated instrument);
4. medicine costs.
Search methods for identification of studies

Pat Spoor developed the search strategies in consultation with the other authors and with Michelle Fiander, Trials Search Co-ordinator (TSC) for the EPOC Group. We searched the Cochrane Database of Systematic Reviews (Issue 11, 2012) for related systematic reviews, and the databases listed below for primary studies. Searches were conducted in November 2012. Exact search dates for each database are included with the search strategies in Appendix A. When we conducted the scoping searches to prepare for this systematic review, we did not identify any studies for inclusion prior to 1980. Also, since 1980 the care of older people in institutionalised facilities has changed significantly due to residents having greater levels of morbidity with an increase in polypharmacy, leading to greater complexity of care. For these reasons, we searched for studies from 1980 onwards to ensure we had studies of relevance to contemporary practice.

Electronic searches

- Cochrane Central Register of Controlled Trials (CENTRAL), The Cochrane Library (Issue 11, 2012)
- EPOC Group Specialised Register, Reference Manager
- MEDLINE, OvidSP (1980 on)
- EMBASE, OvidSP (1980 on)
- AgeLine, EBSCO (1966 on)
- CINAHL (Cumulative Index to Nursing and Allied Health Literature), EBSCO (1980 on)
- International Pharmaceutical Abstracts, OvidSP (1970 on)
- PsycINFO, OvidSP (1980 on)
- Web of Science, Conference Proceedings Citation Index - SSH (ISI Web of Knowledge) (1990 on)
- Web of Science, Conference Proceedings Citation Index - Science (ISI Web of Knowledge) (1990 on)

Search strategies were comprised of keywords and, when available, controlled vocabulary such as MeSH (Medical Subject Headings). The finalised search strategies were developed using an iterative development process in which citations identified by various search terms were screened for relevance by the information specialist. In this manner, individual terms and combinations of terms were assessed as relevant or irrelevant and were included or omitted from the final search strategies. No language restrictions were used. All databases were searched from 1980 on with the exception of AgeLine, which was run from 1966 on, and Web of Science Conference Proceedings indices which were searched from 1990 on.

A Cochrane filter was used to identify RCTs in MEDLINE (Lefebvre 2011). All search strategies, as run, are provided in Appendix 1.

Searching other resources

Grey literature

We conducted a grey literature search to identify studies not indexed in the databases listed above, using the following source:
- Google Scholar

For search terms and number of results, see Appendix 2.

Trials registries

- International Clinical Trials Registry Platform (ICTRP), World Health Organization (WHO) (http://www.who.int/ictrp/en/)

For search terms and number of results, see Appendix 3. We also:
- reviewed reference lists of all included studies, relevant systematic reviews and primary studies;
- contacted authors of relevant studies to clarify reported published information.

Data collection and analysis

Selection of studies

Two review authors (DPA and DKR) independently screened titles and abstracts to decide which studies met the inclusion criteria. Any papers not meeting the inclusion criteria were excluded at this stage. If there was uncertainty or disagreement, consensus was reached by discussion with co-review authors. Two review authors (DA and DKR) independently assessed the full text articles to ensure they still met the inclusion criteria. Full text articles not published in English were translated prior to being assessed for inclusion.

Data extraction and management

Two review authors (DPA and DKR) independently extracted details of articles included in the review, including the study design, the study population, the intervention, usual care, outcome measures used and length of follow-up data, using a specially designed data extraction form based on the EPOC template (EPOC 2009). Where necessary, we contacted authors for missing information or clarification. We intended to use information from the data extraction forms to guide extraction of numerical data for meta-analysis in Review Manager 5 (RevMan 2008). We intended to present data from P-RCTs and C-RCTs using the format in the EPOC working paper on presentation of data (EPOC 2009).
Assessment of risk of bias in included studies

The internal validity of each included study was assessed by two review authors (DPA and DKR). We used The Cochrane Collaboration’s tool for assessing risk of bias (Higgins 2008) based on six standard criteria: adequate sequence generation; concealment of allocation; blinded or objective assessment of primary outcome(s); adequately addressed incomplete outcome data; freedom from selective reporting; freedom from other risk of bias. We used four additional criteria specified by EPOC (EPOC 2009): similar baseline outcome measurements; similar baseline characteristics; reliable primary outcome measures; and adequate protection against contamination. We assessed and reported all included studies in the Cochrane ‘Risk of bias’ tables.

Assessment of the quality of the evidence

The quality of the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria (GRADE 2012).

Measures of treatment effect

We initially planned to conduct a meta-analysis, however, this was not possible due to heterogeneity (see Results). Therefore, we presented a narrative summary of the results. Wherever possible, we presented results with 95% confidence intervals.

Unit of analysis issues

We critically examined the methods of analysis of all study types. We may have identified C-RCTs with unit of analysis errors (for example, randomisation by care home with analysis by residents without adjustments for clustering). If unit of analysis issues had been found, we intended to attempt to re-analyse the data and report the intra-cluster correlation coefficient and adjust for clustering if possible. However, no unit of analysis errors were identified.

Dealing with missing data

We intended to exclude studies from a meta-analysis if there was differential loss to follow-up between groups, greater than 20%. However, as meta-analysis was not appropriate this did not apply.

Assessment of heterogeneity

See Data synthesis section.

Assessment of reporting biases

We intended to examine funnel plots corresponding to meta-analysis of the primary outcome in order to assess the potential for small study effects such as publication bias. However, this was not possible as meta-analysis was not undertaken.

Data synthesis

We intended to synthesise the results of the studies depending on the quality, design and heterogeneity, and we intended to pool the results of studies if at least two studies were homogeneous regarding the participants, interventions and outcomes. As stated above, this was not possible and, therefore, a narrative summary was undertaken. We described studies according to setting, type of intervention and study design together with an assessment of the evidence on the theoretical basis for each of the approaches described.

Subgroup analysis and investigation of heterogeneity

We intended to conduct subgroup analyses for professional and organisational interventions where possible. If we had found that one type of intervention was common, for example medication review, we intended to analyse this separately. If possible, we also planned to undertake subgroup analyses based on the specific nature of the intervention, for example pharmacist-led medication review. However, subgroup analyses were not possible due to heterogeneity.

See Data synthesis section for the investigation of heterogeneity.

Sensitivity analysis

We intended to perform sensitivity analysis for pooled results based on the risk of bias. However, as we could not pool results this did not apply.

RESULTS

Description of studies

See: Characteristics of included studies; Characteristics of ongoing studies.

See: Characteristics of included studies; Characteristics of ongoing studies; Table 1
Results of the search

The search strategy identified 6985 articles for potential inclusion. Following independent screening of titles and abstracts by DPA and DKR, 48 full text articles were assessed for eligibility and eight studies met the inclusion criteria. Two studies are awaiting classification (Beer 2011; Lapane 2011). See Figure 1 (PRISMA flowchart) for details. The search yielded five related systematic reviews (Kaur 2009; Ostini 2009; Verrue 2009; LaMantia 2010; Loganathan 2011) and one narrative review (Markum 2010) and their references were reviewed; no further relevant studies were identified from these.
Figure 1. Study flow diagram.
Included studies

The eight included studies involved 7653 residents in 262 (range 1 to 85) care homes. Three studies were conducted in Australia (Roberts 2001; Crotty 2004a; Crotty 2004b), two in the UK (Furniss 2000; Zermansky 2006), one in Sweden (Claesson 1998), one in the Netherlands (Strikwerda 1994) and one in the USA and Canada (Gurwitz 2008).

Design

Six studies were C-RCTs (Strikwerda 1994; Claesson 1998; Furniss 2000; Roberts 2001; Crotty 2004a; Gurwitz 2008) and two studies were P-RCTs (Crotty 2004b; Zermansky 2006). There was a wide range of study duration and follow-up between the studies, ranging from six weeks to two years (see Table 1).

Participants

All studies involved older people living in care homes (long-term care facilities). Mean age ranged from 81.2 years (Furniss 2000) to 87.2 years (Gurwitz 2008) and the majority of residents were female (range 59.7% (Crotty 2004a) to 77% (Zermansky 2006)). The study by Roberts 2001 did not report mean age or gender. Strikwerda 1994 studied 196 residents in one nursing home, Claesson 1998 studied 1854 residents in 33 nursing homes, Crotty 2004a studied 154 residents in 10 high-level residential facilities, Crotty 2004b studied 110 residents in 85 long-term care facilities, Furniss 2000 studied 330 residents in 14 nursing homes, Gurwitz 2008 studied 1118 residents in 29 units in two long-term care facilities, Roberts 2001 studied 3230 residents in 52 nursing homes and Zermansky 2006 studied 661 residents in 65 nursing and residential homes for older people.

Interventions

The interventions evaluated were diverse and often multifaceted. Medication review (conducted by various methods) was a component of seven studies (Strikwerda 1994; Claesson 1998; Furniss 2000; Roberts 2001; Crotty 2004a; Crotty 2004b; Zermansky 2006). Three studies involved multidisciplinary case-conferencing (Claesson 1998; Crotty 2004a; Crotty 2004b) and two studies involved an educational element for care home staff (Roberts 2001; Crotty 2004a). One study evaluated the use of clinical decision support technology (Gurwitz 2008). Other components of interventions included introducing a new professional role to stakeholders (Roberts 2001) and the transfer of medicines information (Crotty 2004b). Further descriptions of interventions are presented below.

Strikwerda 1994 evaluated the effect of community pharmacist feedback to GPs on their patients' prescriptions over a four week period. Claesson 1998 evaluated the effectiveness of monthly multidisciplinary team meetings between the physician, pharmacist and nurse(s) over 12 months. The aim of the meetings was to discuss and improve the use of drugs. Pharmacists received a total of 65.5 hours of education and training prior to and during the intervention period.

Furniss 2000 investigated the effectiveness of pharmacist-conducted medication review (in addition to usual care by the GP) versus usual care by the GP. The intervention was a single medication review conducted by one pharmacist with access to medical and nursing home records. No details were provided on the education and training of the pharmacist.

The intervention evaluated by Roberts 2001 had three components: (i) introducing a new professional role and relationship building; (ii) nurse education; (iii) medication review by pharmacists holding a postgraduate diploma in clinical pharmacy. Medication reviews were undertaken for a non-random subsample of 500 residents (total intervention residents 905) selected by nursing staff. Most of the contact between pharmacists and GPs was indirect.

Crotty 2004a evaluated the effectiveness of an 'outreach medication advisory service'. This involved a medication review prepared by the pharmacist, followed by two multidisciplinary case conferences held six to 12 weeks apart (with the GP, geriatrician, pharmacist, care staff and an Alzheimer’s Association of South Australia representative). No details were provided on the education and training of the pharmacist.

Crotty 2004b investigated the effectiveness of a pharmacist transition co-ordinator for residents who were being discharged from hospital to a long-term care facility. The intervention focused on the transfer of medicines information to the nursing home staff, GP and the community pharmacist. Following this, a medication review was conducted by the community pharmacist contracted to the care home. In addition, the transition pharmacist co-ordinated a multidisciplinary case conference 14 to 28 days after transfer involving him or herself, the GP, community pharmacist and a nurse.

Zermansky 2006 evaluated the effectiveness of a clinical medication review (in addition to usual care by the GP) undertaken by a pharmacist who held a post-graduate clinical pharmacy qualification versus usual care by the GP. The pharmacist reviewed the medicines with the medical and care home records in conjunction with a consultation with the resident (if possible) and a nurse or carer.
The intervention investigated by Gurwitz 2008 was a clinical decision support system in facilities that had computerised provider order entry systems. The clinical decision support system was designed based on previous research on preventable adverse drug events, criteria for suboptimal prescribing in older people and drug-drug interactions. Warning messages were displayed to prescribers in a pop-up box in real time when medicines were entered into the computer provider order entry system. Prescribers were free to either act on alerts or ignore them.

Outcomes
Outcomes were diverse with differing definitions, methods of data collection, varying time points and different reporting methods. Studies reported measures other than those specified for this review and these are listed in the Characteristics of included studies tables.

Primary outcome measures

Adverse drug events
Only two studies specified adverse drug events as an outcome measure (Crotty 2004b; Gurwitz 2008). However, Crotty 2004b did not define adverse drug events. Adverse drug events were the primary outcome measure in the Gurwitz 2008 study and were defined as ‘an injury resulting from the use of a drug’; such adverse drug events may have resulted from medication errors or from adverse drug reactions in which there was no error.

Hospital admissions
Four studies included hospital admissions as an outcome measure (Furniss 2000; Roberts 2001; Crotty 2004b; Zermansky 2006). Furniss 2000 reported hospital admissions as the number of inpatient days. Roberts 2001 reported the proportion of residents hospitalised and Zermansky 2006 reported the mean number of non-elective hospitalisations per resident. Crotty 2004b grouped together emergency department visits and hospital readmissions.

Mortality
Three studies included mortality as an outcome measure (Furniss 2000; Roberts 2001; Zermansky 2006). Furniss 2000 and Zermansky 2006 reported mortality as the number of deaths over eight and six months, respectively. Roberts 2001 reported the proportion of residents who had died over 12 months together with cumulative survival.

Secondary outcome measures

Quality of life
No studies measured quality of life.

Medication-related problems
Medication-related problems were measured and classified in diverse ways in six studies. Strikwerda 1994 reported the number of pharmacists’ recommendations and described their type. Claesson 1998 described the type and frequency of drug-related problems along with pharmacists’ recommendations. Furniss 2000 measured the number of pharmacist’s recommendations, accepted recommendations by the GP, and the number of treatment changes. Reasons were provided for the pharmacist’s recommendations. Roberts 2001 measured the number of medicine changes likely to be due to medication review. Crotty 2004b identified medication-related problems and classified them into categories. Zermansky 2006 measured the number of changes in medication per participant as the primary outcome; pharmacist’s recommendations were identified, collated and classified along with GPs’ acceptance of the recommendations.

Medication appropriateness
Two studies assessed medication appropriateness using a validated tool (Crotty 2004a; Crotty 2004b). Both studies used the Medication Appropriateness Index (MAI) (Hanlon 1992).

Medicine costs
Four studies calculated medicine costs (Furniss 2000; Roberts 2001; Crotty 2004a; Zermansky 2006). Furniss 2000 calculated drug costs per resident throughout the observation and intervention phases of the study. Roberts 2001 collected yearly drug costs from prescription claims data based on the Australian Pharmaceutical Benefits Scheme. Crotty 2004a calculated monthly drug costs for all regular medicines based on the Australian Pharmaceutical Benefits Scheme. Zermansky 2006 calculated the 28 day net ingredient cost of repeat medicines per resident.

Excluded studies
None reported.

Risk of bias in included studies
Studies were heterogeneous with regard to risk of bias (see Figure 2; Figure 3). Risk of bias is summarised below for each domain.
Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

<table>
<thead>
<tr>
<th>Risk of Bias Item</th>
<th>Low Risk of Bias</th>
<th>Unclear Risk of Bias</th>
<th>High Risk of Bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Subjective outcomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Objective outcomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Primary outcomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Secondary outcomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Similar baseline outcome measurements</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Similar baseline characteristics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reliable primary outcome measure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adequate protection against contamination</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other bias</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Legend:
- **Low risk of bias**
- **Unclear risk of bias**
- **High risk of bias**
Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Crotty 2004a</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>?</td>
<td>?</td>
<td>+</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Crotty 2004b</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Zermansky 2006</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>?</td>
<td>?</td>
</tr>
</tbody>
</table>
Allocation
Six studies were judged to have a low risk of bias based on random sequence generation (Furniss 2000; Roberts 2001; Crotty 2004a; Crotty 2004b; Zermansky 2006; Gurwitz 2008). The studies by Strikwerda 1994 and Claesson 1998 did not report how the sequence was generated. Four studies utilised computer-generated random or pseudo-random numbers (Furniss 2000; Crotty 2004a; Crotty 2004b; Zermansky 2006) and Roberts 2001 drew from a hat. Allocation was adequately concealed via centralisation in both of the P-RCTs (Crotty 2004b; Zermansky 2006). Due to the remaining six studies having a cluster design, they were deemed to be at low risk of bias with regard to allocation concealment (Strikwerda 1994; Claesson 1998; Furniss 2000; Roberts 2001; Crotty 2004a; Gurwitz 2008).

Blinding
Due to the nature of the interventions it was not possible to blind participants and personnel in any of the studies and, therefore, performance bias was judged to be high for each study. Three studies blinded outcome assessment for subjective outcomes (Crotty 2004a; Crotty 2004b; Gurwitz 2008) and, therefore, detection bias for these outcomes was low for these studies and high for the remainder. Detection bias was deemed to be low for objective outcomes for studies that reported them.

Incomplete outcome data
Three studies were deemed at low risk of attrition bias as they reported similar baseline characteristics with a similar number of dropouts for similar reasons (Crotty 2004a; Crotty 2004b; Zermansky 2006). The only outcome in the Claesson 1998 study was a description of medicine-related problems in the intervention group and attrition bias was not relevant. The risk of attrition bias was unclear for four studies due to a lack of information (Strikwerda 1994; Furniss 2000; Roberts 2001; Gurwitz 2008).

Selective reporting
Although there was no evidence of selective reporting in the studies, that is all outcome measures stated in the methods were reported, research protocols were not available and, therefore, there was insufficient information to permit judgement.

Other potential sources of bias

Similar baseline outcome measurements
Three studies (Roberts 2001; Crotty 2004b; Zermansky 2006) were deemed at low risk of bias as baseline outcome measurements were similar. Furniss 2000 was judged to be at high risk of bias because there were fewer deaths in the control group compared with the intervention group. Crotty 2004a was also judged to be at a high risk of bias because of baseline differences in the Medication Appropriateness Index. The three remaining studies were deemed to be at an unclear risk of bias as outcomes were not measured at baseline (Strikwerda 1994; Claesson 1998; Gurwitz 2008).

Similar baseline characteristics
Five studies reported similar baseline characteristics and were judged to be at low risk of bias (Claesson 1998; Roberts 2001; Crotty 2004a; Crotty 2004b; Zermansky 2006). The study by Strikwerda 1994 reported fewer males in group A and fewer medicines in group B compared to group C and was judged to be at high risk. The study by Furniss 2000 was deemed to be at high risk because in the control group the residents were younger and there were fewer females. Gurwitz 2008 was deemed to be at unclear risk because baseline characteristics of residents were not reported (although units were matched for general characteristics, bed size and general characteristics of residents).

Reliable primary outcome measure
All eight studies were deemed to have reliable primary outcome measures (although not all the outcome measures were included in this review).

Adequate protection against contamination
Two studies that were of a cluster design were assessed to be at an unclear risk of adequate protection against contamination because although they were randomised by care home it was unclear whether a GP may have serviced both intervention and control homes (Claesson 1998; Roberts 2001). The study by Crotty 2004a was deemed to be at low risk of contamination because in addition to the cluster design the GPs were checked to avoid contamination between intervention and control residents. The study by Strikwerda 1994 was at high risk because although residents were randomised by GP they all resided in the same nursing home. Furniss 2000 randomised care homes in different geographical areas and was therefore deemed at low risk of contamination. Gurwitz 2008 attempted to limit the crossover of prescribers between intervention and control units, however some prescribers worked simultaneously on both units and consequently the trial was judged to be at high risk of contamination. The two studies that were P-RCTs were deemed to be at high risk as contamination was possible (Crotty 2004b; Zermansky 2006).
Effects of interventions
See: Summary of findings for the main comparison
Due to the heterogeneity in interventions, outcomes and risk of bias, it was deemed inappropriate to conduct a meta-analysis. The effectiveness of the interventions are described below.

Primary outcome measures

Adverse drug events
Crofty 2004b found no evidence of an effect of a pharmacist transition coordinator on adverse drug events (relative risk 1.05, 95% CI 0.66 to 1.68). Gurwitz 2008 tested a clinical decision support system and found no evidence of an effect on all adverse drug events (adjusted rate ratio 1.06, 95% CI 0.92 to 1.23) or preventable adverse drug events (adjusted rate ratio 1.02, 95% CI 0.81 to 1.30).

Hospital admissions
Furniss 2000 found fewer inpatient days per resident in the intervention group compared with the control group during the four month intervention phase of the study (0.55 versus 1.26); however, small numbers precluded statistical analysis. In the Roberts 2001 study, no statistically significant difference was found in the mean proportion of residents hospitalised between the intervention and control groups. Crofty 2004b demonstrated a reduction in the combination of emergency room visits and hospital readmissions with a relative risk ratio of 0.38 (95% CI 0.15 to 0.99) when analysing residents who were alive at follow-up. When residents who had died were included, there was no evidence of an effect on hospital admissions (relative risk 0.98, 95% CI 0.28 to 1.21). Zermansky 2006 showed no evidence of an effect on the mean number of hospitalisations per resident (relative risk 0.75, 95% CI 0.52 to 1.07).

Mortality
Furniss 2000 found fewer deaths in the intervention group compared with the control group during the intervention phase of the study (4 versus 14, P = 0.028); however when the observation phase of the study was taken into account, there was no evidence of deaths in the control and intervention groups were 28 and 26 (P value not reported), respectively. In the Roberts 2001 study, no statistically significant difference was found in the mean proportion of residents who had died between the intervention and control groups. A survival analysis found a hazard ratio of 0.85 (95% CI 0.75 to 0.96) in favour of the intervention group when analysed by individual residents; however after accounting for the clustering effect this was no longer statistically significant (hazard ratio 0.85, 95% CI 0.68 to 1.06). Zermansky 2006 showed no evidence of an effect on the number of deaths (relative risk 1.06, 95% CI 0.70 to 1.64).

Secondary outcome measures

Quality of life
No studies evaluated the effect of interventions on this outcome.

Medication-related problems
Strikwerda 1994 reported that 122 potential medication-related problems were identified in 61 residents. As a result, nine medicines were discontinued and four medicines had a dose reduction. The most common medication-related problem was a potential interaction (51, 42%), followed by dose (31, 25%), indication (23, 19%) and duration of the prescription (17, 14%). Claesson 1998 identified 819 drug-related problems in 395 residents (2.1 per resident). The most common problem was 'choice of drug' (348, 43%), with the majority of these being inappropriate according to Swedish Medical Product Agency guidelines. Two hundred and seventy-six (34%) problems were due to 'unclear indication' whereby the team did not know why a drug had been prescribed or the drug had not been adequately re-evaluated. Ninety per cent (737) of the problems discussed were acted upon, with 368 (45%) resulting in stopping the medicine and 162 (20%) led to a change of medicine. Five hundred and thirty-two medicine changes were evaluated with 404 (76%) still in place after a month, 59 (11%) discontinued and previous therapy room restored, and 69 (13%) were difficult to evaluate as partial changes had occurred.

Furniss 2000 made 261 recommendations of which 239 (92%) were accepted by the GP. This resulted in 144 actual treatment changes. Thirty residents did not require a change in therapy, and the mean number of recommendations per resident (for those who needed at least one recommendation) was 2.46 (range 0 to 7). The most common reasons for recommendations were 'indication for the medication no longer present' (85, 33%) and 'safer or more efficacious use of drug' (77, 30%).

Roberts 2001 followed up 137 of the 500 medication reviews conducted and found that 54 (39%) of the residents had changes likely to be due to the review. No further information was provided.

Crofty 2004b identified medicine-related problems at admission to the long-term care facility for intervention and control residents. The most common issue classified as a medicine-related problem by the authors was that a resident had been appointed a new physician. The next most common problems identified were: discrepancy between medication discharge summary and medication (32, 57% intervention; 26, 48% control); precaution with use (18, 32% intervention; 14, 26% control); no indication for medication (18, 32% intervention; 8, 15% control).
In the study by Zermansky 2006, at least one recommendation was made in 256 (77%, 95% CI 73.1 to 81.7) residents, with a mean of 2.3 recommendations per resident. Six hundred and seventy-two medication-related recommendations were made along with an additional 75 recommendations related to the residents’ conditions. The most common recommendation was technical (for example generic switching, amending quantities, removing discontinued items from the repeat prescription) with 225 (30%) recommendations. Following technical reasons, the most common recommendations were to conduct a test to monitor therapy (161, 22%) and to stop a medicine (100, 13%). The GP accepted 565 (76%) of the pharmacist’s recommendations and rejected 52 (7%); there was no response to the review or the resident died before the review could be actioned in the remaining cases. The GP actioned 433 (77%) of the accepted recommendations.

Medication appropriateness

Crotty 2004a found that, based on the Medication Appropriateness Index (MAI), medication appropriateness improved in the intervention group (MAI mean change 4.1, 95% CI 2.1 to 6.1) compared with the control group (MAI mean change 0.4, 95% CI -0.4 to 1.2). MAI scores were higher at baseline for intervention group residents compared with control residents (mean MAI 7.4, 95% CI 4.5 to 10.3 versus 4.1, 95% CI 2.4 to 5.7). There were no baseline differences in mean MAI scores between the control (3.7, 95% CI 2.2 to 5.2) and intervention groups (3.2, 95% CI 1.8 to 4.6) in the Crotty 2004b study. Following the intervention, there was no change in MAI in the intervention group (2.5, 95% CI 1.4 to 3.7) whereas the MAI in the control group had worsened (6.5, 95% CI 3.9 to 9.1). The difference in MAI scores at follow-up was statistically significant (P = 0.007). The effect of the intervention on MAI scores remained significant when controlled for baseline MAI, Charlson Comorbidity Index and the number of drugs discontinued during hospital admission.

Medicine costs

The cost of medicines per resident in the observation phase of the Furniss study was £142.53 in the control group and £159.01 in the intervention group (Furniss 2000). Following the intervention phase, costs were £141.24 in the control group versus £131.54 in the intervention group, representing a reduction in medicine costs of £27.47 per resident over a four month period. Accounting for the pharmacist’s time, the cost saving on medicines in the intervention group was calculated to be £22/resident. Roberts 2001 calculated a drug cost saving of $AU64 per resident per year in the intervention group compared to the control group. When the cost of the intervention was accounted for, the net cost saving was $AU16 per resident per year. Crotty 2004a found no statistically significant difference in mean medicine costs per month per resident between the intervention and control groups (mean change $AU5.72 intervention versus $AU3.37 control, P = 0.837). Zermansky 2006 found no evidence of an effect of the intervention on the cost of 28 days repeat medicines per resident (mean difference £ -0.70, 95% CI £-7.28 to £5.71).

DISCUSSION

Summary of main results

Eight studies were included in the review and one ongoing study. There was no evidence of an effect of the interventions on any of the primary outcomes of the review that is adverse drug events (Crotty 2004b; Gurwitz 2008), hospital admissions (Furniss 2000; Roberts 2001; Crotty 2004b; Zermansky 2006) and mortality (Furniss 2000; Roberts 2001; Zermansky 2006). No studies included quality of life measures. There was evidence that the interventions led to the identification and resolution of medication-related problems (Strikwerda 1994; Claesson 1998; Furniss 2000; Roberts 2001; Crotty 2004b; Zermansky 2006). There was evidence from two studies that medication appropriateness was improved (Crotty 2004a; Crotty 2004b). However, the link between improved medication appropriateness based on the Medication Appropriateness Index and patient-related outcomes is not clear. The evidence for an effect on medicine costs was equivocal with two studies finding a reduction in costs (Furniss 2000; Roberts 2001) and two studies finding no difference (Crotty 2004a; Zermansky 2006).

Overall completeness and applicability of evidence

The review was designed to identify interventions that considered residents’ whole medication regimens to optimise prescribing. Consequently, a broad range of interventions (professional and organisational) were eligible for the review and diverse, multifaceted interventions were ultimately implemented to address the objectives of the review. The interventions were tested in the population of interest; however, there was considerable variability in the outcomes measured with quality of life not represented in any of the included studies. Current practice varies considerably internationally. However, multidisciplinary teams (involving physicians, nurses and pharmacists) play a significant role in optimising prescribing for care home residents and this was reflected in the studies; the majority of interventions involved multidisciplinary teamwork, usually with pharmacists conducting medication reviews. However, the effectiveness of this has not been demonstrated. Information and communication technology is increasingly being employed to optimise prescribing in many settings, and one study tested the impact of a clinical decision support system (Gurwitz 2008).
Quality of the evidence

Robust conclusions cannot be drawn from the evidence due to variability in design, interventions, outcomes and results. The review included eight studies of varying quality that included 7653 residents living in 262 care homes in six countries. As medication review was the main intervention or a component of the intervention in seven out of the eight studies, the effects of medication review were summarised in the 'Summary of findings' table (Summary of findings for the main comparison). The overall quality of the evidence for the outcomes reported was low or very low. The majority of the included studies were cluster-RCTs and this was appropriate given the complex nature of interventions, the difficulty of blinding and the consequential threat of contamination. The patient-RCTs did not adequately protect against contamination and, therefore, the effects of the intervention may have potentially been diluted. Some of the studies had short follow-up periods, which may have potentially limited the detection of effects on outcomes. None of the studies blinded participants and personnel, however this was unlikely to have been achievable due to the nature of the interventions. The interventions tested were complex and multifaceted and none of the studies attempted to disentangle the 'black box' effect, that is to understand the effects of the contributing components. Not all the studies attempted blinding of assessment for subjective outcomes, and this could have been implemented. A major limitation of the evidence was the diversity of outcome measures and the fact that they differed in the way they were defined (if at all), collected and analysed.

Potential biases in the review process

Bias was minimised when conducting this review by several methods. An extensive literature search was conducted which was guided by EPOC and the included studies from published systematic reviews were screened. Studies were not limited to those in the English language. Two review authors independently screened titles and abstracts, assessed studies for eligibility, evaluated risk of bias and extracted data.

Agreements and disagreements with other studies or reviews

Five previously published systematic reviews (Kaur 2009; Ostini 2009; Verrue 2009; LaMantia 2010; Loganathan 2011) and one narrative review (Markum 2010) related to the objectives of this review were identified. No further studies were identified from these reviews and the conclusions were similar, that is mixed results were obtained from the several intervention types tested in heterogeneous studies.

Authors' conclusions

Implications for practice

The interventions implemented in the studies in this review led to the identification of medication-related problems, confirming that suboptimal prescribing is prevalent in this context. The majority of medication-related problems were resolved through the interventions employed. In addition, evidence from two studies suggested that the appropriateness of medication could be improved through multifaceted interventions involving medication review by pharmacists, transfer of information and multidisciplinary case conferencing. Despite the identification and resolution of medication-related problems, and improvements in medication appropriateness, there is a lack of evidence on how this translates to improvements in resident-related outcomes, namely adverse drug events, hospital admissions, mortality and quality of life. The effect of interventions on medicine costs was unclear, with two studies showing a reduction in costs and two studies showing no difference.

Implications for research

High-quality, adequately powered RCTs, ideally using cluster designs, need to be conducted to identify effective interventions to optimise prescribing for older care home residents. More studies are needed to investigate the effectiveness of clinical decision support systems as well as multidisciplinary interventions in this context. Further work is required to develop consensus on identifying, defining, measuring, reporting and analysing important resident-related outcomes, including quality of life. This will enable meta-analyses to be conducted on future RCTs.

Acknowledgements

We would like to acknowledge the valuable input of Michelle Fianer (Trials Search Coordinator, EPOC group) in refining the search strategy and Sally Dalton (Faculty Team Librarian, University of Leeds) for helping to run the searches, as well as the helpful comments of peer reviewers on the protocol, Luciana Ballini, Kirby Lee, Aaron Tejani, Craig Ramsay, and the support of Lisa Bero. We would like to thank the members of the EPOC group in Canada and the UK for their help and advice. We would also like to acknowledge Mrs Julie Sowter (School of Healthcare, University of Leeds) and Noorjte Arts (Institute for Linguistics, University of Utrecht) for translating the Strikwerda paper from Dutch to English and Mrs Denise Buttress (School of Healthcare, University of Leeds) for invaluable secretarial support.
References to studies included in this review

Claesson 1998 [published data only]

Crotty 2004a [published data only]

Crotty 2004b [published data only]

Furniss 2000 [published data only]

Gurwitz 2008 [published data only]

Roberts 2001 [published data only]

Strikwerda 1994 [published data only]

Zermansky 2006 [published data only]

References to studies awaiting assessment

Beer 2011 [published data only]

Lapane 2011 [published data only]

References to ongoing studies

Desborough [published data only]

Additional references

Alldred 2007a

Alldred 2007b

Interventions to optimise prescribing for older people in care homes (Review)

Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Interventions to optimise prescribing for older people in care homes (Review)

Armour 2002

Barber 2009

Beers 1992

Beglinger 2008

Brymer 2003

Christensen 2011

Crotty 2004

Department of Health 2001

EPOC 2009

Fahey 2003

Furniss 2000

GRADE 2012

Gray 2003

Gurwitz 2005

Hanlon 1992

Hanlon 1996

Higgins 2008

Howard 2007

Kaur 2009

LaMantia 2010

Lau 2005
Lau DT, Kasper JD, Potter DEB, Lyles A, Bennett RG. Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Archives of Internal Medicine 2005; 165:68–74.

Lefebvre 2011
Loganathan 2011

Markum 2010

Matthews 2002

Oborne 2003

Office for National Statistics 2010

Ostini 2009

Patterson 2012

Perri 2005

RevMan 2008

Rollason 2003

Sloane 2002

Soe 2009

Spinewine 2007

United Nations 2009

Verrue 2009

Zermansky 2006

* Indicates the major publication for the study
### Characteristics of included studies

**[ordered by study ID]**

**Claesson 1998**

| Methods | Cluster-RCT (randomised by nursing home)  
<table>
<thead>
<tr>
<th></th>
<th>Total study duration: 14 months</th>
</tr>
</thead>
</table>
| **Participants** | 1854 residents  
|         | 33 nursing homes  
|         | Setting: nursing homes  
|         | Age: Average 83 years  
|         | Gender: Intervention 70% female; control 67% female  
|         | Country: Sweden  
|         | Date of study: 1994/95 |
| **Interventions** | The aim of the regular multidisciplinary meetings was to discuss and improve the use of drugs in nursing homes, and to decrease the use of drugs which, according to the advice of the workshop arranged by the Swedish Medical Products Agency, could cause confusion and impaired memory. In group discussions, the physician, pharmacist, one or more of the nursing home nurses, and in many cases, one or more of the assistant nurses and nurse aides reviewed the drug use of all residents on a monthly basis over a period of one year. The length and frequency of the meetings were adjusted by the participants to local conditions. The therapy changes that were discussed were thus based on the physician's medical knowledge, the pharmacist's pharmaceutical knowledge, and the nurses' and other staff's knowledge about the patients' social and functional status. The selected pharmacists were educated prior to and during the intervention period. This education took the form of lectures and workshops, which took place on five occasions, twice before the intervention started and three times during the intervention period, for a total of 65.5 hours. The lectures were given by recognised experts, including clinical pharmacists, geriatricians, gerontologists, nurses and two community pharmacists with experience in nursing home consulting. Topics covered were gerontology/geriatrics (12.5 hours), drug use in the elderly (23.5 hours) and basic training in collaborative methods (18.5 hours). In addition, the pharmacists worked with patient cases in small groups, covering all the areas mentioned above (11 hours). In addition to the formal education, the pharmacists formed regional networks. The networking took place locally, whenever the pharmacist felt a need to have it. In order to make the networks constructive, the whole group was instructed by an educational specialist on one occasion |
| **Outcomes** | Medication-related problems  
|         | Not used for this review:  
|         | Drug use |
| **Notes** | Supported by the National Corporation of Swedish Pharmacies and the Swedish Pharmaceutical Society |

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>

Interventions to optimise prescribing for older people in care homes (Review)

Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Claesson 1998  *(Continued)*

| Random sequence generation (selection bias) | Unclear risk | Homes were matched in pairs then each randomised to control or intervention. [Attempted to contact author for further information but unsuccessful] |
| Allocation concealment (selection bias) | Low risk | Cluster design |
| Blinding of participants and personnel (performance bias) | High risk | Blinding not conducted |
| Blinding of outcome assessment (detection bias) | High risk | Blinding not conducted |
| Blinding of outcome assessment (detection bias) | Unclear risk | No objective outcomes |
| Incomplete outcome data (attrition bias) | Unclear risk | Not measured in this study |
| Incomplete outcome data (attrition bias) | Low risk | Medication-related problems described for residents receiving intervention |
| Selective reporting (reporting bias) | Unclear risk | Insufficient information to permit judgement |
| Similar baseline outcome measurements | Unclear risk | Medication-related problems not measured at baseline |
| Similar baseline characteristics | Low risk | Similar baseline characteristics reported |
| Reliable primary outcome measure | Low risk | Drug use |
| Adequate protection against contamination | Unclear risk | Cluster design. [Attempted to contact author for further information but unsuccessful] |
| Other bias | Low risk | Appears to be free of other sources of bias |
### Methods
Cluster-RCT (randomised by care facility)  
Total study duration: 3 months

### Participants
- **10 facilities (5 intervention, 5 control). 154 residents (50 intervention, 54 control, 50 within-facility control)**  
- **Setting:** High-level residential aged-care facilities (nursing homes)  
- **Age:** Intervention mean 85.3, control mean 83.6, within-facility control mean 84.6  
- **Gender:** Intervention male 22 (44%), control male 23 (43%), within-facility control male 17 (34%)  
- **Country:** Australia  
- **Date of Study:** 1999 [Author contacted]

### Interventions
- Outreach geriatric medication advisory service, case conferencing and medication review  
  GPs were invited to attend two multidisciplinary case conferences conducted 6-12 weeks apart. The resident’s GP, a geriatrician, a pharmacist, residential care staff and a representative of the Alzheimer’s Association of South Australia attended the case conferences, which were held at the facility. Residential care staff expanded on any issues in the case notes that required discussion and the Alzheimer’s Association of South Australia representative discussed non-pharmacological management of dementia-related behaviour.  
  Each case conference was chaired by the GP, who used their medical records in addition to case notes from the facility. A problem list was developed by the GP in conjunction with the care staff and a medication review was conducted prior to each case conference.  
  All facilities in the study, including those in the control group, received a half-day workshop provided by the Alzheimer’s Association of South Australia, which examined the use of a toolkit in the management of challenging behaviours.

### Outcomes
- Measured at baseline and three months post-intervention:  
  - Medication appropriateness (MAI)  
  - Drug costs (based on Australian Government Pharmaceutical Benefits Scheme)  
- Not used in this review:  
  - Nursing Home Behaviour Problem Scale (NHBPS)  
  - Number of drugs

### Notes

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Computer-generated random numbers used</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>A researcher independent to the investigators generated the random sequence and cluster design. Staff were asked to “nominate” 20 residents from intervention sites and 10 residents from control sites. From</td>
</tr>
</tbody>
</table>
### Crotty 2004a (Continued)

<table>
<thead>
<tr>
<th>Risk Assessment</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
</tr>
<tr>
<td>All outcomes</td>
<td>No blinding conducted</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
</tr>
<tr>
<td>Subjective outcomes</td>
<td>Assessed by independent pharmacist blinded to allocation [author contacted]</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
</tr>
<tr>
<td>Objective outcomes</td>
<td>No blinding conducted, however outcomes not likely to be influenced by lack of blinding</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
</tr>
<tr>
<td>Primary outcomes</td>
<td>Not measured in this study</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
</tr>
<tr>
<td>Secondary outcomes</td>
<td>Reasons for attrition reported (all due to deaths) and no statistically significant difference found in the proportion of residents lost between groups. Described as intention-to-treat analysis by authors</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
</tr>
<tr>
<td>Insufficient information to permit judgement</td>
<td></td>
</tr>
<tr>
<td>Similar baseline outcome measurements</td>
<td>High risk</td>
</tr>
<tr>
<td>There were differences in the Medication Appropriateness Index between groups at baseline: Control 4.1 (95% CI 2.4-5.7); Within-facility control 6.0 (95% CI 3.1-9.0); Intervention 7.4 (95% CI 4.5-10.3)</td>
<td></td>
</tr>
<tr>
<td>Similar baseline characteristics</td>
<td>Low risk</td>
</tr>
<tr>
<td>Similar baseline characteristics reported</td>
<td></td>
</tr>
<tr>
<td>Reliable primary outcome measure</td>
<td>Low risk</td>
</tr>
<tr>
<td>Medication Appropriateness Index</td>
<td></td>
</tr>
<tr>
<td>Adequate protection against contamination</td>
<td>Low risk</td>
</tr>
<tr>
<td>Cluster design. Randomised by care facility. GP's were checked to avoid contamination between intervention and control residents [author contacted]. No significant differences found between the within-facility control and the control groups, therefore no evidence of a carry-over effect of the intervention</td>
<td></td>
</tr>
</tbody>
</table>
Crotty 2004a  (Continued)

<table>
<thead>
<tr>
<th>Other bias</th>
<th>Low risk</th>
<th>Appears to be free of other sources of bias</th>
</tr>
</thead>
</table>

Crotty 2004b

<table>
<thead>
<tr>
<th>Methods</th>
<th>RCT (randomised by patient)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total study duration: 8 weeks</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Participants</th>
<th>110 patients (56 intervention, 54 control) from three hospitals discharged to 85 long-term facilities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Setting: Long-term care facilities</td>
<td></td>
</tr>
<tr>
<td>Age: Mean 82.7, s.d. 6.4</td>
<td></td>
</tr>
<tr>
<td>Gender: 67 women (60.9%), 43 men (39.1%)</td>
<td></td>
</tr>
<tr>
<td>Country: Australia</td>
<td></td>
</tr>
<tr>
<td>Date of study: October 2002 to July 2003</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Pharmacist transition coordinator.</th>
</tr>
</thead>
<tbody>
<tr>
<td>The intervention focused on transferring information on medications to care providers in the long-term care facilities, including the nursing staff, the family physician and the accredited community pharmacist. On the patient’s discharge from the hospital to the long-term care facility both the family physician and the community pharmacist were faxed a medication transfer summary compiled by the transition pharmacist and signed by the hospital medical officer. This communication supplemented the usual hospital discharge summary and included specific information on changes to medications that had been made in the hospital and aspects of medication management that required monitoring. After transfer of the patient to the long-term care facility, the transition pharmacist co-ordinated an evidence-based medication review that was to be performed by the community pharmacist contracted to the facility within 10 to 14 days of the transfer. The transition pharmacist also co-ordinated a case conference involving him or herself, the family physician, the community pharmacist and a registered nurse at the facility within 14 to 28 days of the transfer. At this case conference, the transition pharmacist provided information concerning medication use and appropriateness. The usual hospital discharge process received by the control group included a standard hospital discharge summary.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Measured at baseline and eight weeks post-discharge:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse drug events (not defined)</td>
<td></td>
</tr>
<tr>
<td>Hospital admissions (emergency department visits and hospital readmissions)</td>
<td></td>
</tr>
<tr>
<td>Medication-related problems</td>
<td></td>
</tr>
<tr>
<td>Medication appropriateness (MAI)</td>
<td></td>
</tr>
<tr>
<td>Not used for this review:</td>
<td></td>
</tr>
<tr>
<td>Falls</td>
<td></td>
</tr>
<tr>
<td>Worsening mobility</td>
<td></td>
</tr>
<tr>
<td>Worsening behaviours</td>
<td></td>
</tr>
<tr>
<td>Increased confusion</td>
<td></td>
</tr>
<tr>
<td>Worsening pain</td>
<td></td>
</tr>
<tr>
<td>Risk of bias</td>
<td>Authors’ judgement</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td><strong>Random sequence generation</strong></td>
<td>Low risk</td>
</tr>
<tr>
<td>(selection bias)</td>
<td></td>
</tr>
<tr>
<td><strong>Allocation concealment</strong></td>
<td>Low risk</td>
</tr>
<tr>
<td>(selection bias)</td>
<td></td>
</tr>
<tr>
<td><strong>Blinding of participants</strong></td>
<td>High risk</td>
</tr>
<tr>
<td>and personnel (performance bias)</td>
<td></td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
</tr>
<tr>
<td><strong>Blinding of outcome assessment</strong></td>
<td>Low risk</td>
</tr>
<tr>
<td>(detection bias)</td>
<td></td>
</tr>
<tr>
<td>Subjective outcomes</td>
<td></td>
</tr>
<tr>
<td><strong>Blinding of outcome assessment</strong></td>
<td>Low risk</td>
</tr>
<tr>
<td>(detection bias)</td>
<td></td>
</tr>
<tr>
<td>Objective outcomes</td>
<td></td>
</tr>
<tr>
<td><strong>Incomplete outcome data</strong></td>
<td>Low risk</td>
</tr>
<tr>
<td>(attrition bias)</td>
<td></td>
</tr>
<tr>
<td>Primary outcomes</td>
<td></td>
</tr>
<tr>
<td><strong>Incomplete outcome data</strong></td>
<td>Low risk</td>
</tr>
<tr>
<td>(attrition bias)</td>
<td></td>
</tr>
<tr>
<td>Secondary outcomes</td>
<td></td>
</tr>
<tr>
<td><strong>Selective reporting</strong></td>
<td>Unclear risk</td>
</tr>
<tr>
<td>(reporting bias)</td>
<td></td>
</tr>
<tr>
<td><strong>Similar baseline outcome</strong></td>
<td>Low risk</td>
</tr>
<tr>
<td>measurements</td>
<td></td>
</tr>
<tr>
<td><strong>Similar baseline characteristics</strong></td>
<td>Low risk</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Reliable primary outcome</strong></td>
<td>Low risk</td>
</tr>
<tr>
<td>measure</td>
<td></td>
</tr>
</tbody>
</table>
Adequate protection against contamination | High risk | Randomised by patient therefore contamination possible
---|---|---
Other bias | Low risk | Appears to be free of other sources of bias

**Furniss 2000**

<table>
<thead>
<tr>
<th>Methods</th>
<th>Cluster-RCT (randomised by care home) Total study duration: 8 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>330 residents (172 control, 158 intervention); 14 homes (7 matched pairs) Setting: Nursing homes Age: Control mean 78.9 sd 13.7; intervention mean 83.5 sd 9.2 Gender: Control 115 (67%) females; intervention 125 (79%) females Country: UK Date of study: Not stated</td>
</tr>
<tr>
<td>Interventions</td>
<td>Medication review by pharmacist Medication review by the study pharmacist in the GP's surgery, at the nursing home or (in exceptional circumstances) over the telephone. The pharmacist collected details of current medication for each resident from the medicines administration record chart in the home, together with a brief medical history and any current problems identified by the home staff. Three weeks after the medication review, the homes were revisited, to ascertain whether there had been any immediate problems with the changes in medication and to see if the suggested changes have been implemented</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Measured at time 0 (beginning of study), time 1 at four months (beginning of intervention) and at time 2 at eight months (end of intervention): Hospital admissions (&quot;inpatient days&quot;) Mortality Medication-related problems (number of pharmacist recommendations, acceptance of recommendations by the GP, number of treatment changes) Medication costs (not defined, £ sterling) Not used for this review: Mini-Mental State Examination (MMSE) Geriatric Depression Scale (GDS) Brief Assessment Schedule Depression Cards (BASDEC) Crichton-Royal Behaviour Rating Scale (CRBRS) Number of drugs per resident Type of drugs Reason for neuroleptic use Use of primary and secondary care resources Number of accidents Falls</td>
</tr>
<tr>
<td>Notes</td>
<td>Funded by the North West NHS Executive</td>
</tr>
</tbody>
</table>

**Risk of bias**
### Furniss 2000  (Continued)

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Computer-generated pseudo random numbers used</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Homes were randomised at the start of the start of a four-month observation phase. Cluster design</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>No blinding described</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>No blinding conducted</td>
</tr>
<tr>
<td>Subjective outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>No blinding conducted, however outcomes not likely to be influenced by lack of blinding</td>
</tr>
<tr>
<td>Objective outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>Insufficient reporting of attrition/exclusions to permit judgement</td>
</tr>
<tr>
<td>Primary outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>Insufficient reporting of attrition/exclusions to permit judgement</td>
</tr>
<tr>
<td>Secondary outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Insufficient information to permit judgement</td>
</tr>
<tr>
<td>Similar baseline outcome measurements</td>
<td>High risk</td>
<td>14 (8.1%) deaths in control group versus 22 (13.9%) deaths in intervention group at baseline. No baseline measurements of other primary outcomes of this review</td>
</tr>
<tr>
<td>Similar baseline characteristics</td>
<td>High risk</td>
<td>Slightly fewer residents in the intervention group (158) versus control (172). In the control group, residents were younger (mean 78.9 s.d. 13.7 versus mean 83.5 s. d. 9.2) and there were fewer females (67% versus 79%)</td>
</tr>
<tr>
<td>Reliable primary outcome measure</td>
<td>Low risk</td>
<td>Crichton-Royal Behaviour Rating Scale</td>
</tr>
<tr>
<td>Adequate protection against contamination</td>
<td>Low risk</td>
<td>Randomised by care home (which were in different geographical areas)</td>
</tr>
</tbody>
</table>
### Gurwitz 2008

<table>
<thead>
<tr>
<th>Methods</th>
<th>Cluster-RCT (randomised by care unit within two long-term care facilities) Total study duration: 12 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>1,118 resident in 29 units in two long-term care facilities Setting: Long-term care facilities Age: Average 87.2 years Gender: 71.3% female Country: US and Canada Date of study: 2006-7 [Author contacted]</td>
</tr>
<tr>
<td>Interventions</td>
<td>Computerised provider order entry with clinical decision support A team of geriatricians, pharmacists, health services researchers and information system specialists designed the clinical decision support system The team reviewed the types of preventable adverse drug events based on previous research and widely accepted published criteria for suboptimal prescribing in elderly people available at the time of this study. All serious drug-drug interactions from a standard pharmaceutical drug interaction database were also reviewed and alerts were included for a limited number of more than 600 potentially serious interactions that were reviewed. For residents on the intervention units, the alerts were displayed in a pop-up box to prescribers in real time when a drug order was entered. The pop-up boxes were informational; they did not require specific actions from the prescriber and did not produce or revise orders automatically. On the control units, the alerts were not displayed to the prescribers</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Measured throughout study period (resident-months): Adverse drug event (&quot;an injury resulting from the use of a drug&quot; includes medication error and adverse drug reaction) Severity of adverse drug event Preventability of adverse drug event</td>
</tr>
<tr>
<td>Notes</td>
<td>Supported by the Agency for Healthcare Research and Quality.</td>
</tr>
</tbody>
</table>

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Block randomisation used. Within each block, units were randomly assigned using the random function in Microsoft Excel®. [Author contacted]</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Cluster design</td>
</tr>
<tr>
<td>Bias</td>
<td>Risk</td>
<td>Notes</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>-------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Blinding of participants and personnel</td>
<td>High</td>
<td>Not conducted</td>
</tr>
<tr>
<td>(performance bias)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection</td>
<td>Low</td>
<td>Outcome assessors were blind to allocation</td>
</tr>
<tr>
<td>bias)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjective outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection</td>
<td>Unclear</td>
<td>No objective outcomes</td>
</tr>
<tr>
<td>bias)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Objective outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear</td>
<td>Insufficient reporting of attrition/exclusions to permit judgement</td>
</tr>
<tr>
<td>Primary outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear</td>
<td>Not measured in this study</td>
</tr>
<tr>
<td>Secondary outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear</td>
<td>Insufficient information to permit judgement</td>
</tr>
<tr>
<td>Similar baseline outcome measurements</td>
<td>Unclear</td>
<td>No baseline measurements of adverse drug effects</td>
</tr>
<tr>
<td>Similar baseline characteristics</td>
<td>Unclear</td>
<td>Baseline characteristics not reported, however, units were matched for bed size and general characteristics of residents and the unit</td>
</tr>
<tr>
<td>Reliable primary outcome measure</td>
<td>Low</td>
<td>Number of adverse drug events</td>
</tr>
<tr>
<td>Adequate protection against contamination</td>
<td>High</td>
<td>Cluster design. Efforts were made to limit crossover of prescribers between intervention and control units, however, some prescribers worked simultaneously on both intervention and control units. In an effort to assess the possibility that this may have led to changes in behaviour in the control group, the rate of responses to “unseen” alerts in the control units during the first versus the last quarter of the study was assessed at one of the study sites. The rate of response was lower in the last quarter, suggesting that prescribers did not adopt new habits due to seeing alerts on intervention units</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low</td>
<td>Appears to be free of other sources of bias</td>
</tr>
</tbody>
</table>
### Methods
Cluster-RCT (randomised by care home)
Total study duration: Two years

### Participants
3230 residents (905 intervention, 13 homes); 2325 control, 39 homes)
Setting: Nursing homes
Age:
- Intervention: <60 2.0%, 60-69 6.6%, 70-79 21.9%, 80-89 47.4%, 90-99 20.7%, ≥ 100 1.7%
- Control: <60 2.6%, 60-69 5.4%, 70-79 22.3%, 80-89 46.7%, 90-99 21.1%, ≥ 100 1.6%
Gender: Not reported
Country: Australia
Date of Study: Not reported

### Interventions
Three phase intervention: introducing a new professional role to stakeholders with relationship building; nurse education; and medication review by pharmacists.

The clinical pharmacy service model introduced to each nursing home was supported with activities such as focus groups facilitated by a research nurse, written and telephone communication, and face-to-face professional contact between nursing home staff and clinical pharmacists on issues such as drug policy and specific resident problems, together with education and medication review by pharmacists holding a postgraduate diploma in clinical pharmacy. This was a multifaceted intervention directly targeting nursing homes. Most of the contact with GPs was indirect, using the existing relationships between nursing homes and visiting GPs. A number of focus groups and personal interviews about the project were conducted with GPs. In intervention homes, problem-based education sessions (6±9 seminars totalling approximately 11 h per home) were provided to nurses. Sessions addressed basic geriatric pharmacology and some common problems in long-term care (depression, delirium and dementia, incontinence, falls, sleep disorders, constipation and pain). Sessions were supported by wall charts, bulletins, telephone calls and clinical pharmacy visits, averaging 26 h contact per home over the study. Written, referenced drug regimen reviews were prepared by the clinical pharmacists for 500 individual residents selected by the nursing home staff. The reviews highlighted the potential for:
1. adverse drug effects,
2. ceasing one or more drugs,
3. adding drugs,
4. better use of specific drug therapy, particularly psychoactive drugs,
5. nondrug interventions, and
6. adverse effect and drug response monitoring.

Initial reports (61% of total) were audited by a geriatrician before dissemination. Reports were placed in each resident’s nursing home records, made available to the resident’s GP and discussed with nursing staff. Drugs commonly targeted in reviews and education sessions included laxatives, histamine H2-receptor antagonists, allopurinol, quinine, antibacterials, paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs) and psychoactive drugs.

### Outcomes
Measured at baseline and 12 months post-intervention:
- Hospital admissions (not defined)
- Mortality (survival also assessed at 22 months)
- Medication-related problems
- Medication costs (per resident per year based on prescription claims data)
Not used for this review:
- Adverse events (from incident reports)
- Resident Classification Instrument (RCI)
Roberts 2001  (Continued)

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Notes</td>
<td>Supported by the Commonwealth Government of Australia under the Pharmaceutical Education Program</td>
<td></td>
</tr>
</tbody>
</table>

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Homes were assigned to intervention or control by being “drawn from a hat”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Cluster design</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>No blinding conducted</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>No blinding reported</td>
</tr>
<tr>
<td>Subjective outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>No blinding reported, however outcomes not likely to be influenced by lack of blinding</td>
</tr>
<tr>
<td>Objective outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>Insufficient reporting of attrition/exclusions to permit judgement</td>
</tr>
<tr>
<td>Primary outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>Insufficient reporting of attrition/exclusions to permit judgement</td>
</tr>
<tr>
<td>Secondary outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Insufficient information to permit judgement</td>
</tr>
<tr>
<td>Similar baseline outcome measurements</td>
<td>Low risk</td>
<td>Slight imbalance in mortality and hospitalisations at baseline; however this was accounted for in the analysis</td>
</tr>
<tr>
<td>Similar baseline characteristics</td>
<td>Low risk</td>
<td>Similar baseline characteristics reported</td>
</tr>
<tr>
<td>Reliable primary outcome measure</td>
<td>Low risk</td>
<td>Mortality and Resident Classification Instrument (RCI)</td>
</tr>
<tr>
<td>Adequate protection against contamination</td>
<td>Unclear risk</td>
<td>Cluster design. [Attempted to contact author for further information but no response]</td>
</tr>
</tbody>
</table>
Roberts 2001  (Continued)

| Other bias | High risk | Medication reviews were undertaken for a non-random subsample of 500 residents (total intervention residents 905) selected by nursing staff |

Strikwerda 1994

<table>
<thead>
<tr>
<th>Methods</th>
<th>RCT (randomised by GP)</th>
<th>Total study duration: 6 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>196 residents</td>
<td>One nursing home</td>
</tr>
<tr>
<td></td>
<td>Age: mean 84.5 years (59-100)</td>
<td>Gender: 25% male</td>
</tr>
<tr>
<td></td>
<td>Country: Netherlands</td>
<td>Date of study: 1993</td>
</tr>
<tr>
<td>Interventions</td>
<td>Feedback on GP prescribing from community pharmacist</td>
<td>Group A received usual care, group B GPs issued with a medication list used by their patients, group C GPs received a medication list plus feedback from community pharmacist</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Medication-related problems</td>
<td>Not used for this review: drug use</td>
</tr>
</tbody>
</table>

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Insufficient information to permit judgement</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Cluster design</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>No blinding conducted</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Subjective outcomes</td>
<td>Unclear risk</td>
<td>Insufficient information to permit judgement</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Objective outcomes</td>
<td>Unclear risk</td>
<td>Not measured in this study</td>
</tr>
</tbody>
</table>
### Zermansky 2006

**Methods**
- RCT (randomised by patient)
- Total study duration: 6 months

**Participants**
- 661 (331 intervention, 330 control) care home residents, 65 care homes
- Setting: Nursing and residential homes for older people
- Age: Intervention mean 85.3 (IQR 81-90); control mean 84.9 (IQR 80-90)
- Gender: Intervention 75 (22.7%) male; control 79 (23.9%) male
- Country: UK
- Date of study: 2002

**Interventions**
- Medication review by a single pharmacist.
  - A clinical medication review was conducted by the study pharmacist who held a postgraduate qualification in clinical pharmacy within 28 days of randomisation. It comprised a review of the GP clinical record and a consultation with the resident and carer. The pharmacist formulated recommendations with the resident and carer and passed them on a written proforma to the GP for acceptance and implementation. GP acceptance was signified by ticking a box on the proforma. Control patients received usual GP care

**Outcomes**
- Measured at baseline and six months ± three weeks post-randomisation:
  - Hospital admissions (non-elective)
  - Mortality
Medication-related problems
Medicine costs (cost of 28 days of repeat medicines per participant)
Not used for this review:
Number of changes in medicines per participant
Number of medicines per participant
Recorded medication reviews
Falls
SMMSE
Barthel index
Number of GP consultations

Notes
Funded by The Health Foundation, 90 Long Acre, London WC2 9RA (Registered Charity Number 286967)

<table>
<thead>
<tr>
<th>Risk of bias</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bias</strong></td>
</tr>
<tr>
<td>Random sequence generation (selection bias)</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Subjective outcomes</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Objective outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Primary outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Secondary outcomes</td>
</tr>
</tbody>
</table>
Selective reporting (reporting bias) | Unclear risk | Insufficient information to permit judgement
--- | --- | ---
Similar baseline outcome measurements | Low risk | Similar baseline measurements for hospital admissions and medicine costs
Similar baseline characteristics | Low risk | Similar baseline characteristics reported
Reliable primary outcome measure | Low risk | Number of changes in medication
Adequate protection against contamination | High risk | Randomised by patient therefore contamination possible
Other bias | Unclear risk | Sample size calculation indicated that 1600 residents were required, however, only 661 residents were recruited

**Characteristics of ongoing studies [ordered by study ID]**

**Desborough**

<table>
<thead>
<tr>
<th>Trial name or title</th>
<th>Multi-professional clinical medication reviews in care homes for the elderly: study protocol for a randomised controlled trial with cost effectiveness analysis</th>
</tr>
</thead>
</table>
| Methods | Cluster RCT (randomised by care home)  
Total Study Duration: 12 months |
| Participants | Residents of 30 care homes for older people (average age >65) |
| Interventions | Intervention homes will receive a multi-professional medication review at baseline and at 6 months, with follow-up at 12 months. Control homes will receive usual care (support they currently receive from the National Health Service), with data collection at baseline and 12 months |
| Outcomes | Emergency hospital admissions and Accident and Emergency (A&E) visits (number of admissions in six months per patient)  
Mortality  
Potentially inappropriate prescribing (number of drugs which match the STOPP criteria at each data collection point)  
Medication costs (mean drug costs per patient - net ingredient costs for 28 days)  
Not used for this review:  
Number of falls (mean per patient per month)  
Utilisation of primary care, secondary care and personal social services health professional time (GP, nurse and other) |
| Starting date | 2011 |
| Contact information | --- |
DATA AND ANALYSES

This review has no analyses.

ADDITIONAL TABLES

Table 1. Summary of study characteristics

<table>
<thead>
<tr>
<th>Study,Country, Design</th>
<th>Participants</th>
<th>Intervention</th>
<th>Outcome measures</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Claesson 1998 Sweden Cluster-RCT</td>
<td>1854 residents in 33 nursing homes</td>
<td>Multidisciplinary meetings with physician, pharmacist and nurse(s)</td>
<td>Medication-related problems</td>
<td>14 months</td>
</tr>
<tr>
<td>Crotty 2004a Australia Cluster-RCT</td>
<td>154 residents in 10 nursing homes</td>
<td>Multidisciplinary case conferencing with GP, a geriatrician, a pharmacist, residential care staff and an Alzheimer’s Association representative</td>
<td>Medication Appropriateness Index</td>
<td>3 months</td>
</tr>
<tr>
<td>Crotty 2004b Australia Patient-RCT</td>
<td>110 patients discharged to 85 long-term care facilities</td>
<td>Pharmacist transition co-ordinator. Transfer of medicines information to nursing staff, family physician and community pharmacist plus medication review and case conferencing</td>
<td>Adverse drug events, Hospital admissions, Medication-related problems, Medication Appropriateness Index</td>
<td>8 weeks</td>
</tr>
<tr>
<td>Furniss 2000 UK Cluster-RCT</td>
<td>330 residents in 14 nursing homes</td>
<td>Medication review by a single pharmacist</td>
<td>Hospital admissions, Mortality, Medication-related problems, Medicine costs</td>
<td>8 months</td>
</tr>
<tr>
<td>Gurwitz 2008 USA/Canada Cluster-RCT</td>
<td>1118 residents in 29 units in 2 long-term care facilities</td>
<td>Computerised provider order entry with clinical decision support</td>
<td>Adverse drug events</td>
<td>12 months</td>
</tr>
<tr>
<td>Roberts 2001 Australia Cluster-RCT</td>
<td>3230 residents in 52 nursing homes</td>
<td>Introduction of new professional role, nurse education and medication review by pharmacists</td>
<td>Hospital admissions, Mortality, Medication-related problems, Medicine costs</td>
<td>24 months</td>
</tr>
<tr>
<td>Strikwerda 1994 Netherlands Cluster-RCT</td>
<td>196 residents in 1 nursing home</td>
<td>Feedback on GP prescribing from community pharmacist</td>
<td>Medication-related problems</td>
<td>6 weeks</td>
</tr>
</tbody>
</table>
Table 1. Summary of study characteristics (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Characteristics</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zermansky 2006</td>
<td>661 residents in 65 care homes</td>
<td>Medication review by a single pharmacist</td>
</tr>
<tr>
<td>UK Patient-RCT</td>
<td>Medication-related problems</td>
<td>Hospital admissions</td>
</tr>
<tr>
<td></td>
<td>Medicine costs</td>
<td>Mortality</td>
</tr>
<tr>
<td></td>
<td>6 months</td>
<td>Medication-related problems</td>
</tr>
</tbody>
</table>

APPENDICES

Appendix 1. Electronic database search strategies

Cochrane Database of Systematic Reviews Issue 11, 2012, Wiley

Search run 16th November 2012

Number of results: 6

#1 MeSH descriptor Polypharmacy, this term only (71)
#2 (polypharm*:ti,ab,kw (158)
#3 (multi-drug* or multitdrug*) NEAR/2 (therapy or therapies or prescribing or treatment or regime*):ti,ab,kw (263)
#4 (beer NEAR/2 criter*):ti,ab,kw (9)
#5 (appropriate or optim* or inappropriat* or suboptim* or sub-optim* or unnecessary or incorrect* or in-correct* or excessive or multiple or concurrent*) NEAR/2 (medicine* or medication* or prescription* or drug*):ti,ab,kw (1415)
#6 (over NEAR/1 prescript*) or (overprescrib* or overprescript*):ti,ab,kw (29)
#7 (under NEAR/1 prescript*) or (underprescrib* or underprescript*):ti,ab,kw (6)
#8 "medication appropriateness index":ti,ab,kw (15)
#9 (quality NEAR/1 (prescribing or prescription* or medication*)):ti,ab,kw (30)
#10 (improv* NEAR/1 (prescrib* or prescription* or pharmaco*)):ti,ab,kw (147)
#11 "case conferencing":ti,ab,kw (9)
#12 MeSH descriptor Medication Therapy Management, this term only (18)
#13 "medication* management":ti,ab,kw or "medication* therapy management":ti,ab,kw or "medication* strategy":ti,ab,kw or "medication* strategies":ti,ab,kw or (medication* NEAR/2 review*):ti,ab,kw (408)
#14 "drug regimen review":ti,ab,kw or (drug NEAR/1 utiliation NEAR/2 (review* or evaluat*)):ti,ab,kw (126)
#15 MeSH descriptor Drug Utilization Review, this term only (102)
#16 "drug related problem":ti,ab,kw or (prescription* NEAR/2 pattern*):ti,ab,kw or "Assessing care of vulnerable elders":ti,ab,kw or (acove):ti,ab,kw or (stopp):ti,ab,kw (122)
#17 "start screening tool":ti,ab,kw or "Screening Tool of Older Person's Prescriptions":ti,ab,kw or "Screening Tool to Alert doctors to Right Treatment":ti,ab,kw (0)
#18 MeSH descriptor Medication Errors, this term only (163)
#19 (pharmaceutical* or pharmacist* or prescrib*):ti,ab,kw (11159)
#20 MeSH descriptor Pharmaceutical Preparations, this term only (225)
#21 MeSH descriptor Pharmacists, this term only (325)
#22 MeSH descriptor Pharmacists' Aides, this term only (5)
#23 MeSH descriptor Prescription Drugs, this term only (45)
#24 MeSH descriptor Drug Prescriptions, this term only (402)
#25 MeSH descriptor Pharmaceutical Services, this term only (93)
#26 MeSH descriptor Drug Toxicity, this term only (359)
#27 (pharmacotherap*):ti,ab,kw (6758)
#28 MeSH descriptor Drug Therapy, this term only (425)
Interventions to optimise prescribing for older people in care homes (Review)

40

Cochrane Central Register of Controlled Trials (CENTRAL) Issue 11, 2012, Wiley

Search run 16th November 2012

Number of results: 281

#1 MeSH descriptor Polypharmacy, this term only (71)
#2 (polypharm*:ti,ab,kw (158)
#3 (multi-drug* or multidrug*) NEAR/2 (therapy or therapies or prescribing or treatment or regime*):ti,ab,kw (263)
#4 (beerp NEAR/2 criter*):ti,ab,kw (9)
#5 (appropriate or optim* or inappropriat* or sub-optim* or unnecessary or incorrect* or in-correct* or excessive or multiple or concurrent* ) NEAR/2 (medicine* or medication* or prescription* or drug*):ti,ab,kw (1415)
#6 (over NEAR/1 prescript*) or (overprescrib* or overprescrip*):ti,ab,kw (29)
#7 (under NEAR/1 prescript*) or (underprescrib* or underprescript*):ti,ab,kw (6)
#8 "medication appropriateness index":ti,ab,kw (15)
#9 (quality NEAR/1 (prescribing or prescription* or medication*)):ti,ab,kw (30)
#10 (improv* NEAR/1 (prescrib* or prescription* or pharmaco*)):ti,ab,kw (147)
#11 "case conferencing":ti,ab,kw (9)
#12 MeSH descriptor Medication Therapy Management, this term only (18)
#13 "medication* management":ti,ab,kw or "medication* therapy management":ti,ab,kw or "medication* strategy":ti,ab,kw or "medication* strategies":ti,ab,kw or (medication* NEAR/2 review*):ti,ab,kw (408)
#14 "drug regimen review":ti,ab,kw or (drug NEAR/1 utili?ation NEAR/2 (review* or evaluat*)):ti,ab,kw (126)
#15 MeSH descriptor Drug Utilization Review, this term only (102)
#16 "drug related problem":ti,ab,kw or (prescription* NEAR/2 pattern*):ti,ab,kw or "Assessing care of vulnerable elders":ti,ab,kw or (acove):ti,ab,kw or (stopp):ti,ab,kw (122)
#17 "start screening tool":ti,ab,kw or "Screening Tool of Older Person's Prescriptions":ti,ab,kw or "Screening Tool to Alert doctors to Right Treatment":ti,ab,kw (0)
Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity-maximizing version (2008 revision); Ovid format

1 randomized controlled trial.pt.
2 controlled clinical trial.pt.
3 randomized.ab.
4 placebo.ab.
5 drug therapy.fs.
6 randomly.ab.
7 trial.ab.
8 groups.ab.
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10 exp animals/ not humans.sh.
11 9 not 10

MEDLINE, 1980-, OvidSP
Search run 16th November 2012 [database last updated November, week 2, 2012]
Number of results: 1381
1 polypharmacy/ (1998)
2 polypharm*.ti,ab. (2606)
3 ((multi-drug* or multidrug*) adj2 (therapy or therapies or prescribing or treatment or regime*).ti,ab. (2285)
4 (beer* adj1 criter*).ti,ab. (187)
5 ((appropriate or optim* or inappropriat* or suboptim* or sub-optim* or unnecessary or incorrect* or in-correct* or excessive or multiple or concurrent*) adj2 (medicine? or medication? or prescription* or drug*).ti,ab. (16485)
6 ((over adj1 prescript*) or (overprescrib* or overprescript*)).ti,ab. (542)
7 ((under adj prescript*) or (underprescrib* or underprescript*).ti,ab. (215)
8 medication appropriateness index.ti,ab. (52)
9 (quality adj (prescribing or prescription? or medication?)).ti,ab. (70)
10 (improv* adj (prescrib* or prescription? or pharmaco*).ti,ab. (1512)
11 case conferencing.ti,ab. (40)
12 medication therapy management/ (445)
13 (medication? management or medication? therapy management or medication? strategy or medication? strategies or (medication? adj2 review*).ti,ab. (2391)
14 drug regimen review*.ti,ab. (52)
15 drug utilization review/ (2780)
16 (drug adj utilization adj2 (review* or evaluat*).ti,ab. (348)
17 drug related problem?.ti,ab. (702)
18 ((prescribing or prescription?) adj2 pattern?).ti,ab. (2205)
19 Assessing care of vulnerable elders.ti,ab. (43)
20 acove.ti,ab. (30)
21 stopp.ti,ab. (43)
22 start screening tool.ti,ab. (10)
23 Screening Tool of Older Person’s Prescriptions.ti,ab. (11)
24 Screening Tool to Alert doctors to Right Treatment.ti,ab. (9)
25 Medication Errors/ (9580)
26 (pharmaceutical? or pharmacist? or prescrib*).ti,ab. (142522)
27 pharmaceutical preparations/ (45187)
28 Pharmacists/ (9723)
29 Pharmacists’ Aides/ (489)
30 Prescription Drugs/ (2261)
31 Drug Prescriptions/ (20951)
32 Pharmaceutical Services/ (3895)
33 drug toxicity/ (5710)
34 pharmacotherap*.ti,ab. (18959)
35 drug therapy/ (33168)
36 drug monitoring/ (12728)
37 or/1-36 [Prescribing/medication terms] (279642)
38 Homes for the Aged/ or “homes for the aged”.tw. (10633)
39 exp Nursing Homes/ or nursing home?.tw. (30522)
40 (aged adj2 (care or nursing or healthcare or residential) adj2 (facility or facilities or home?!)).ti,ab. (268)
41 ((geriatric or elderly) adj2 (facility or facilities or care home?!).ti,ab. (296)
42 Hospitals, Veterans/ (5454)
43 or/38-42 [Care facilities- aged terms] (40335)
44 ((care or convalescent) adj (home? or center? or centre? or facility or facilities)).ti,ab. (26613)
45 ((skilled or intermediate) adj (nursing facility or nursing facilities)).ti,ab. (1272)
46 (resident* adj2 (care or facility or facilities)).ti,ab. (4925)
47 ((nursing or group or residential) adj home?!).ti,ab. (20829)
48 Long-Term Care/ (20740)
49 ((longterm or long term) adj3 (care or facility or facilities)).ti,ab. (14906)

Interventions to optimise prescribing for older people in care homes (Review)

Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Interventions to optimise prescribing for older people in care homes (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Interventions to optimise prescribing for older people in care homes (Review)

Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
random allocation. ti, ab. (1267)
randomly allocated. ti, ab. (18323)
allocated randomly. ti, ab (1885)
(allocated adj 2 random). ti, ab. (869)
single blind*. ti, ab. (13170)
double blind*. ti, ab. (142385)
((treble or triple) adj 2 blind*). ti, ab. (388)
prospective study/ (220972)
or/66-81 (1227757)
case study/ or case report. ti, ab. (287404)
abstract report/ or letter/ (870000)
or/83-84 (1153094)
82 not 85 [SIGN RCT filter minus placebo] (1196147)
39 and (46 or 65) and 86 (3579)
limit 87 to yr = "1980-Current (3530)

EPOC Group, Specialised Register, Reference Manager
Search run November 2012
Number of results: 565

1 All Non-Indexed [prescrib*] OR [prescription*] OR [medication* use] OR [drug therapy*] OR [polypharmacy]
2 AND Title, primary [improv*] OR [optimi*] OR [rational] OR [irrational] OR [evidence*]
3 OR Keywords [7] [prescrib*] AND [practice*]
4 OR Keywords [7] [prescrib*] AND [improv*]
5 OR Keywords [7] [prescrib*] AND [compliance*]
6 OR Abstract [25] [rational] AND [prescrib*]
7 OR Abstract [25] [irrational] AND [prescrib*]
8 OR Abstract [25] [improv* prescrib*] OR [optim* prescrib*] OR [rational prescrib*]
9 OR Abstract [25] [irrational prescrib*] OR [reduc*overprescrib*]
10 OR Title, primary [improv*] AND [medicine*]
11 OR All Non-Indexed unnecessary prescrib*
12 OR Abstract [25] [polypharmacy*] AND [reduc*]
13 OR Keywords [7] [prescrib*] AND [adher*]
14 OR Keywords [7] medication adherence*

OR ALL Non-Indexed fields: ACOVE or STARTT found one more citation; total 565 -

Ageline, 1966-, EBSCO

Search run November 2012
Number of results: 186

S1 TI (prescribing or polypharm* or pharmacist* ) or SU (prescribing or polypharm* )
S2 TX (appropriat* w2 prescrib*) OR (inappropriat* w2 prescrib*) OR (optim* w2 prescrib*) or (suboptim* w2 prescrib*) or (sub-optim* w2 prescrib*) or (unnecessary n2 medicat*) or (unnecessary n2 prescrib*) or TX medication* w2 appropriat* or (appropriat* w2 medicat*) OR (inappropriat* w2 medicat*) or (optim* w2 medicat*) or (suboptim* w2 medicat*) or (sub-optim* w2 medicat*) or overprescrib* or overmedicat* or "over-medicat*"
S3 TX "Assessing care of vulnerable elders" or TX "Screening Tool of Older Person's Prescriptions" OR TX "Screening Tool to Alert doctors to Right Treatment" OR TX "start screening tool" or "beers criteria" or "beers criteria"
S4 TX overprescrib* or inappropriat* prescribe*
S5 DE "Nursing Homes" OR TX "nursing home" or TX "nursing homes"
S6 TX (care w2 home* OR care w2 facility or care w2 facilities) or TX ("homes for the aged" or "old age home") or TX ("geriatric homes")
S7 TX nursing w2 home*
S8 S5 or S6 or S7
S9 (drug w1 therap*) or (drug w2 utili*)
S10 SU (prescription or prescriptions or pharma*)
S11 DE "Medication Errors"
S12 SU drug OR SU drugs or SU medication*
S13 TI medication error*
S14 (S9 or S10 or S11 or S12 or S13) AND S8
S15 (S1 or S2 or S3 or S4) and S8
S16 SU (trial or trials) or SU studies or TI (study or trial) or TX (control w3 area or control w3 cohort* or control w3 compar* or control w3 condition* or control w3 group* or control w3 intervention* or control w3 participant* or control w3 study) or TX (random* OR controlled)
S17 (S14 OR S15) AND S16

CINAHL (Cumulative Index to Nursing and Allied Health Literature), 1980-, EBSCO

Search run 16th November 2012
Number of results: 407

S1 MH polypharmacy (1,327)
S2 TI polypharmacy or AB polypharmacy (784)
S3 TI beer* n1 criter* or AB beer* n1 criter* (113)
S4 TI (appropriate N2 medici* or optim* N2 medici* or inappropriat* N2 medici* or sub-optim* N2 medici* or unnecessary N2 medici* or incorrect* N2 medici* or in-correct* N2 medici* or excess* N2 medici* or multip* N2 medici* or concurrent* N2 medici*) or AB (appropriate N2 medici* or optim* N2 medici* or inappropriat* N2 medici* or sub-optim* N2 medici* or unnecessary N2 medici* or incorrect* N2 medici* or in-correct* N2 medici* or excess* N2 medici* or multip* N2 medici* or concurrent* N2 medici*) or TI (appropriate N2 medici* or optim* N2 medici* or inappropriat* N2 medici* or sub-optim* N2 medici* or unnecessary N2 medici* or incorrect* N2 medici* or in-correct* N2 medici* or excess* N2 medici* or multip* N2 medici* or concurrent* N2 medici*) or TI (appropriate N2 prescription* or optim* N2 prescription* or inappropriat* N2 prescription* or sub-optim* N2 prescription* or unnecessary N2 prescription* or incorrect* N2 prescription* or in-correct* N2 prescription* or excess* N2 prescription* or multip* N2 prescription* or concurrent* N2 prescription*) or AB (appropriate N2 prescription* or optim* N2 prescription* or inappropriat* N2 prescription* or sub-optim* N2 prescription* or unnecessary N2 prescription* or incorrect* N2 prescription* or in-correct* N2 prescription* or excess* N2 prescription* or multip* N2 prescription* or concurrent* N2 prescription*) or TI (over n2 prescript* or overprescrib* or overprescript*) or AB (over n2 prescript* or overprescrib* or overprescript*) (369)
S5 TI ("under prescript" or underprescrib* or underprescript*) or AB ("under prescript" or underprescrib* or underprescript*) (55)
S6 TI ("medication appropriateness index" or AB "medication appropriateness index") (19)
S7 TI (quality n2 prescription* or quality n2 medication*) or AB (quality n2 prescription* or quality n2 medication*) (234)
S9 TI (improv* n2 prescription* or improv* n2 pharma* or AB (improv* n2 prescription* or improv* n2 pharma*) (458)
S10 TI "Assessing care of vulnerable elders" or AB "Assessing care of vulnerable elders" (31)
S11 TI acove or AB acove (20)
Interventions to optimise prescribing for older people in care homes (Review)

Copyight © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
null
Drug distribution system?.ti,ab,hw. (1890)
(medication? management or medication? therapy management or medication? strategy or medication? strategies or (medication? adj2 review?)).ti,ab,hw. (1868)
drug toxicity.ti,ab,hw. (456)
Screening Tool of Older Person’s Prescriptions.ti,ab. (3)
Screening Tool to Alert doctors to Right Treatment.ti,ab. (6)
(pharmaceutical adj (preparation? or care?)).ti,ab,hw. (7739)
pharmacotherap*.ti,ab,hw. (3820)
drug therap*.ti,ab,hw. (8197)
(drug adj utilization adj2 (review* or evaluat*)).ti,ab,hw. (4848)
drug regimen review*.ti,ab,hw. (194)
case conferencing.ti,ab,hw. (0)
o/t1-29 [Prescribing/medication terms] (122563)
Home? for the Aged.ti,ab,hw. (13)
(aged adj2 (care or nursing or healthcare or residential) adj2 (facility or facilities or home?)).ti,ab,hw. (30)
((geriatric or elderly) adj2 (facility or facilities or care home?)).ti,ab,hw. (44)
o/t31-33 [Aged care homes] (82)
((skilled or intermediate) adj nursing facil*).ti,ab,hw. (207)
(resident* adj2 (care or facilit*)).ti,ab. (371)
((nursing or group or residential) adj home?).ti,ab. (1296)
((longterm or long term) adj3 (care or facilit*)).ti,ab. (1407)
residential home?.ti,ab,hw. (52)
assisted living.ti,ab,hw. (101)
(life care cen* or continued care cen* or extended care facil*).ti,ab,hw. (64)
Halfway house*.ti,ab. (3)
o/t31-40 [Other residential care] (2911)
(ageing or aging or gerontol* or elder* or geriatric* or seniors or old age or late? life).ti,ab,hw. (13967)
(old* adj (person* or people or adult* or patient* or inpatient* or outpatient*)).ti,ab. (3200)
veteran*.ti,ab. (1377)
o/t44-46 [Elderly terms] (17017)
43 and 47 (1089)
30 and (34 or 48) (720)
limit 49 to yr="1980 -Current" (703)

PsycINFO, 1980-, OvidSP
Search run 19th November 2012 [Database last updated November, week 2, 2012]
Number of results: 905

1 Polypharmacy/ (639)
2 polypharm*.ti,ab. (1043)
3 (beer* adj1 criter*).ti,ab. (57)
4 ((inappropriate or optim* or adverse or inappropriat* or suboptim* or sub-optim* or unnecessary or incorrect* or in-correct* or excess* or multip* or concurrent*) adj2 (medicine? or medication? or prescription* or drug*)).ti,ab. (3911)
5 ((over adj1 prescript*) or (overprescrib* or overprescript*)).ti,ab. (136)
6 ((under adj1 prescript*) or (underprescrib* or underprescript*)).ti,ab. (35)
7 medication appropriateness index*.ti,ab. (14)
8 (quality adj1 (prescription* or medication*)).ti,ab. (39)
9 (improv* adj1 (prescription* or pharmaco*)).ti,ab. (94)
10 (drug related problem? or (prescription adj2 pattern?)).ti,ab. (509)
11 Assessing care of vulnerable elders.ti,ab. (37)
12 above.ti,ab. (25)
Appendix 2. Google scholar search strategy

Searched 16th November 2012
Number of results: 59

(prescription* or prescribing or drug* or medicine* or medication* or pharmaco* or polypharmacy) and (residential or care home* or care facilit* or nursing home*) and (elder* or aged* or old* or seniors or geriatric* or gerontol*) Books excluded. No date limit.

Appendix 3. WHO trial registry search strategy

Search run 26th November 2012 [Database last updated 26th November 2012]
Number of results: 2

Each term 1 was searched with each possible combination of the other terms (2-4). Terms were combined using AND

<table>
<thead>
<tr>
<th>Term 1</th>
<th>Term 2</th>
<th>Term 3</th>
<th>Term 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomised</td>
<td>Nursing homes</td>
<td>elderly drugs</td>
<td></td>
</tr>
<tr>
<td>Randomized</td>
<td>Residential homes</td>
<td>old medication</td>
<td></td>
</tr>
<tr>
<td>RCT</td>
<td>pharmacy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomly</td>
<td></td>
<td>polypharmacy</td>
<td></td>
</tr>
</tbody>
</table>

Interventions to optimise prescribing for older people in care homes (Review)
CONTRIBUTIONS OF AUTHORS

David Alldred conceived and co-ordinated the review and is the guarantor of the review. David Alldred prepared the protocol with support and advice from Carmel Hughes, Nick Barber, David Raynor, Pat Spoor and Tim Chen. Pat Spoor designed the search strategy with input from David Alldred and ran the searches. All authors were involved in the retrieval of papers. David Alldred and David Raynor screened the search results, assessed retrieved papers against the eligibility criteria, appraised the quality of the papers and extracted data from the papers. David Alldred was responsible for entering data into RevMan and drafting the review with input from all authors.

DECLARATIONS OF INTEREST

David Alldred and David Raynor are co-authors on a study that was included in this review (Zermansky 2006).

SOURCES OF SUPPORT

Internal sources

- School of Healthcare, University of Leeds, UK.

Funding was provided for the services of Ms Pat Spoor to develop the search strategy and run the searches.

External sources

- No sources of support supplied

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

We intended to pool results and conduct meta-analyses if studies were homogeneous. However, as studies were heterogeneous, this was not undertaken. Similarly, subgroup analyses were not possible.

INDEX TERMS

Medical Subject Headings (MeSH)

*Homes for the Aged; *Nursing Homes: Drug Prescriptions [*standards]; Inappropriate Prescribing [*prevention & control]; Medication Reconciliation; Quality Improvement [*standards]; Randomized Controlled Trials as Topic

MeSH check words

Aged; Humans